Alchemab Therapeutics Ltd

Alchemab Therapeutics is a pharmaceutical company focused on developing antibody therapies for hard-to-treat diseases such as neurodegeneration and cancer. The company has developed a unique platform that identifies naturally occurring protective antibodies from resilient individuals, those who are able to overcome or resist disease despite being genetically predisposed to it. This platform integrates deep B cell sequencing, computational analysis and advanced proteomics to pinpoint antibodies with therapeutic potential.

Alchemab's approach flips traditional drug discovery on its head by starting with patient response and using that information to identify key targets and therapeutic antibodies. The company has several programs in preclinical development, including potential treatments for frontotemporal dementia, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, and various types of cancer. Alchemab is headquartered in London, UK, with labs in Cambridge, UK and Boston, US, and collaborates with various academic institutions, biobanks, and charities to access and analyze patient samples.

Alchemab Therapeutics is a pharmaceutical company dedicated to identifying and developing naturally occurring therapeutic antibodies from resilient individuals, those who overcome or resist disease despite genetic predisposition or other risk factors. By analyzing the unique antibody repertoires of these resilient individuals, Alchemab aims to unlock nature's engineering and harness the power of the human immune system to discover and develop groundbreaking treatments for prevalent, hard-to-treat diseases, such as neurodegenerative conditions and cancer, where current treatments are limited.

Alchemab Therapeutics promotes a collaborative and ambitious culture, fostering innovation and a strong sense of purpose. They value diverse perspectives and expertise, emphasizing the power of teamwork in tackling challenging diseases. This culture is evident in their numerous partnerships with academic institutions, biobanks, and charities, as well as their commitment to leveraging cutting-edge technology and computational approaches. The company also places importance on creating a supportive and inclusive environment for their employees, recognizing that a talented and motivated workforce is essential for achieving their goals.